(Finance) – Ulysses Biomeda healthcare biotech company listed on Euronext Growth Milan, expects that i revenues 2024including grants, are equal to approximately 950 thousand eurosderiving mainly from the sales of products and services represented by the Group’s new integrated solutions. THE’EBITDA 2024 is expected negative at around 2.2 million eurosan improvement compared to what was achieved in 2023 mainly due to the combined effect of the increase in revenues from sales of products and services and the benefits of corporate restructuring.
The guidance of revenues 2025including grants, is estimated within a range between 1.4 and 1.6 million euroswith an average estimated increase of 40% compared to the same revenues expected for 2024. Management expects this increase to come mainly from the organic growth of sales deriving from the Medical and Platform divisions. The guidance of EBITDA 2025 is estimated negative in a range between -600 and -400 thousand euroswith a significant improvement thanks to the expected increase in revenues from the sale of products and services as well as the effect of corporate restructuring and cost reduction actions.
The growth guidance of revenues in the period 2025-2028 (including grants) is estimated to maintain a CAGR between 26% and 30%reaching a revenue range of between 2.8 and 3.5 million euros in 2028. This increase over the period is expected to derive mainly from the organic growth of the sale of UBM products integrated and validated on Hyris System, relating to the Medical division, thanks to access to new foreign markets, mainly in Europe.
In the period 2025-2028, management estimates a progressive improvement in profitability; theThe Group’s EBITDA is expected to be positive in financial year 2026. The range of EBITDA guidance in the period 2025-2028 is impacted not only by the absolute trend in the value of revenues, but also by the gradual increase in variable and fixed costs, which are expected to grow gradually and proportionally compared to the increase in revenues in the same time frame. The 2028 EBITDA is seen at 450-800 thousand euros.